SCHEMBL20119790

SCHEMBL20119790

NC(=O)c1cc2c(NCc3ccco3)nc(Cl)nc2[nH]1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.48
AURKA O14965 1/20 0.46
RPS6KB1 P23443 1/20 0.46
AURKB Q96GD4 1/20 0.46
KMT2A Q03164 7/20 0.45
MAPT P10636 5/20 0.42
LMNA P02545 4/20 0.42
HTT P42858 2/20 0.42
RECQL P46063 1/20 0.42
APP P05067 1/20 0.41
MEN1 O00255 4/20 0.41
PKM P14618 1/20 0.41
HSD17B10 Q99714 1/20 0.41
SOS1 Q07889 1/20 0.41
POLB P06746 2/20 0.41
KDM4E B2RXH2 2/20 0.41
MAPK1 P28482 1/20 0.41
BLM P54132 1/20 0.41
PDE5A O76074 1/20 0.41
REN P00797 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20119893 0.88 SMN1; SMN2 (0.47) SMN1; SMN2KMT2AMAPTLMNAHTT
SCHEMBL20119431 0.86 SMN1; SMN2 (0.46) SMN1; SMN2KMT2AMAPTLMNAHTT
SCHEMBL20119410 0.85 KMT2A (0.51) SMN1; SMN2KMT2AMAPTLMNAHTT
SCHEMBL20119677 0.84 REN (0.53) SMN1; SMN2KMT2AMAPTLMNAHTT
SCHEMBL20119419 0.81 SMN1; SMN2 (0.51) SMN1; SMN2KMT2AMAPTLMNAHTT
SCHEMBL20119401 0.81 SMN1; SMN2 (0.53) SMN1; SMN2KMT2AMAPTLMNAHTT
SCHEMBL24390706 0.79 SMN1; SMN2 (0.49) SMN1; SMN2KMT2AMAPTLMNAHTT
SCHEMBL20119989 0.79 SMN1; SMN2 (0.49) SMN1; SMN2AURKARPS6KB1AURKBKMT2A
Hydrochloric Acid SCHEMBL29238805 0.78 SMN1; SMN2 (0.48) SMN1; SMN2KMT2AMAPTLMNAHTT
SCHEMBL20119588 0.78 SMN1; SMN2 (0.50) SMN1; SMN2KMT2AMAPTLMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-20230279007-A1 Compounds for Improving mRNA Splicing THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES 2023-09-07 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-11702417-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2023-07-18 US disclosed
US-20200283441-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2020-09-10 US disclosed
US-10676475-B2 Compounds for improving mRNA splicing THE GENERAL HOSPITAL CORPORATION (US) 2020-06-09 US disclosed
US-20180118748-A1 Compounds for Improving mRNA Splicing THE GENERAL HOSPITAL CORPORATION 2018-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230279007-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885AURKA 4532/4885RPS6KB1 458/4885
US-10676475-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885AURKA 4532/4885RPS6KB1 458/4885
US-20180118748-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885AURKA 4532/4885RPS6KB1 458/4885
US-11702417-B2 Compounds for improving mRNA splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885AURKA 4532/4885RPS6KB1 458/4885
US-20200283441-A1 Compounds for Improving mRNA Splicing RTCB, RBM17, HNRNPA2B1 SMN1; SMN2 11/4885AURKA 4532/4885RPS6KB1 458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.